USA Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this remains a complex and challenging field, leading neuroscience biotechs – three of which are profiled below – to develop very…
Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
Taiwan A genuinely healthy lifestyle can help prevent neurodegenerative disease Charles S.Y. Yang discusses how his background in physics and quantum sensing led to the founding of MagQu, pioneering ultra-sensitive blood biomarker diagnostics for Alzheimer’s and other neurodegenerative diseases. He explains the company’s SQUID-based technology, commercial journey, regulatory ambitions and funding…
China Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord injury, MSA and ALS have remained among the most difficult conditions to treat, with available therapies largely focused on managing…
Germany Transformation often reveals itself not through grand declarations, but through the decisions organisations make about where to invest, what capabilities to build, and how they choose to serve patients. At Angelini Pharma Germany, that evolution is taking shape through a growing commitment to Brain Health, a resilient Consumer Health business,…
France France Alzheimer’s Joel Jaouen and Benoit Durand articulate a comprehensive strategic framework for addressing one of Europe’s most pressing healthcare challenges. With four decades of operational excellence, the organisation has evolved from a grassroots family initiative into France’s premier associative research funder, developing sophisticated care pathways whilst advocating for systemic…
USA Neurvati Neurosciences is carving a distinctive path in one of medicine’s most high-risk arenas: neuroscience. In this interview, President and CEO Dr Bruce Leuchter explains how a private equity-inspired model, backed by Blackstone Life Sciences, is enabling the company to advance late-stage assets, forge global partnerships, and build a values-driven…
Global As neuroscience reclaims a place at the top table of pharmaceutical innovation, Bristol Myers Squibb (BMS) is quietly reshaping its presence in the field. Spearheaded by its Neuroscience Thematic Research Center, the company is pursuing a dual mandate: to slow the progression of diseases like Alzheimer’s while also addressing their…
Denmark Ian Laquian’s journey from Big Pharma strategy leadership to entrepreneurial venture creation exemplifies the innovative thinking required to address intractable neurological challenges. Having spearheaded CNS therapeutic area strategy at Takeda Pharmaceuticals, Laquian has pioneered a ground-breaking approach that leverages metabolic pathways to treat neurodegenerative diseases. Through the establishment of Kariya…
Singapore Charles Stacey, President and CEO of Cerecin, discusses the company’s strategic direction and partnerships as it advances its Alzheimer’s treatment into Phase 3 trials. He highlights the importance of collaboration with global contract research organizations and large vendors during the clinical development phase. Stacey also shares insights into Cerecin’s approach…
Saudi Arabia Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease. As people live longer, the threat of age-related diseases deepens. Alzheimer’s, one of the cruellest such diseases, therefore represents an increasingly urgent public health challenge in…
Europe The Women’s Brain Foundation, formerly the Women’s Brain Project, has evolved into a fully-fledged foundation dedicated to advancing research in gender precision medicine with a strong focus on brain health. CEO pro-bono Dr Antonella Santuccione Chadha comments on the organisation’s newly extended global reach, progress in understanding the link between…
See our Cookie Privacy Policy Here
